Oncolytics initiated at Ladenburg

Oncolytics initiated with a Buy at Ladenburg. Ladenburg Thalmann analyst Wangzhi Li started Oncolytics Biotech with a Buy rating and $22 price target. The analyst believes Oncolytics is “significantly under-recognized and undervalued, and presents an attractive investment opportunity.” The company’s lead program Pelareorep is a RNA reovirus oncolytic virus that has been safely dosed in greater than 1,100 patients across a variety of cancers, Li points out.
https://thefly.com/landingPageNews.php?id=2797573